Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE, France--(BUSINESS WIRE)--#immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)...

Promising Efficacy and Safety With Four-Week Extended Dosing Data Shows Dose-Dependent Reduction of LDH and Increased Hemoglobin Levels That Demonstrate Clinically Meaningful Hemolysis Inhibition CANbridge Plans to Advance to Pivotal Trial CANbridge to Hold Investor CallBEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc....

- Data Presented During Oral Session at EASL 2023 Demonstrate Fazirsiran’s Promising Impact on Key Markers of Liver Disease - AATD-LD is a Rare Genetic Disease Affecting Children and Adults with no Approved Treatments - Takeda and Arrowhead are Advancing Fazirsiran...

ExxonMobil’s Liza projects produced 11.6 million barrels of crude in May, at 374,450 barrels per day (bpd). This was constituted by production of 4.8 million barrels at Liza Phase 1, and 4.8 million barrels at Phase 2.  May output also...

– All six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide) and had improved glycemic control while reducing or eliminating insulin use – – The two patients with at least one year of follow-up met the criteria...

Construction is well underway on the world’s first high-volume eVTOL aircraft manufacturing facility in Covington, Georgia, USA Experienced Stellantis personnel are providing expertise alongside Archer teams to prepare efficient, innovative manufacturing operations Stellantis recently increased its strategic shareholding in Archer through...

Oral presentation for the ROSEWOOD trial of BRUKINSA in relapsed or refractory follicular lymphoma Additional presentations expand existing evidence base for BRUKINSA across B-cell malignancies BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global...

Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today...

IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET® platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas IPH6501 is progressing towards a Phase 1 clinical trial in 2023 MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Innate Pharma SA...

Carbios has recently consolidated key partnerships with Indorama Ventures and Novozymes, and has announced funding and investment of over €150 million for the first PET biorecycling plant in the world the cost of which has been re-estimated at €230...